Diagnostics for glycaemic monitoring and ketosis testing on show

EKF Diagnostics has announced that its online exhibition booth at ENDO Online 2020 is open for live chats on its range of diagnostics products for glycaemic monitoring and ketosis testing on 10–17 June.

Organised by the Endocrine Society, ENDO Online 2020 runs to 20 June featuring a combination of live and on-demand programming, as well as its virtual Exhibit Hall. This gives researchers and clinicians access to the latest information in endocrinology without having to leave their office. As the current pandemic has cancelled many meetings, making access to learning opportunities and new science challenging, visitors can register for free online access to ENDO Online 2020.

On EKF’s booth (https://endoonline.endocrine.org/exhibitor-EKF) visitors will be able to find out about the company’s line of diagnostic tests and analysers used in glycaemic monitoring and ketosis. These products are used in laboratories, hospitals and clinics worldwide. Visitors can discuss their needs directly with EKF personnel in live chats during designated hall hours (10.00 am to 12.00 noon [EDT]) on 10–13 and 15–17 June.

Key product highlights from EKF include the Lucica Glycated Albumin-L manufactured by Asahi Kasei Pharma. This test is US Food and Drug Administration (FDA)-cleared for sale in the USA, and sold exclusively by EKF as a specific intermediate glycaemic control marker. It delivers a specific quantitative determination of glycated albumin (GA) in serum on compatible clinical chemistry analysers with open-channel capability. The Lucica GA has been one of the most widely used and published enzymatic GA methods in the world.

EKF also offers multiple options for measurement of beta-hydroxybutyrate (BHB), the main ketone-body produced during diabetic ketoacidosis (DKA).  Measuring the level of BHB is clinically useful in both diagnosing ketoacidosis earlier and monitoring the results of treatment. 

The LiquiColor B-HB test features liquid, ready-to-use reagents and is intended for the quantitative measurement of BHB with serum or plasma on compatible clinical chemistry analysers with open-channel capability.

Also to be introduced is EKF’s new STAT-Site WB, a point-of-care BHB and glucose testing device. The STAT-Site WB dual analyte measurement system is easy to use and provides reliable quantitative results in just 5–10 seconds. It is intended for whole-blood, multiple-patient use in professional healthcare settings as an aid to monitor the effectiveness of a diabetes control programme.

www.ekfdiagnostics.com